Edwards Lifesciences Corporation (EW)EWEdwards Lifesciences Corporation

Financials

Quarterly Income Statement (USD)

Quarterly Report	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024	09/30/2024	06/30/2024
Revenue	6.303B	1.649B	1.570B	1.553B	1.532B	1.413B	1.386B	1.354B	1.386B
Cost of Goods Sold	1.388B	359.300M	340.600M	345.200M	342.600M	301.600M	292.200M	262.900M	297.800M
Gross Profit	4.918B	1.289B	1.229B	1.210B	1.190B	1.111B	1.094B	1.091B	1.088B
Gross Profit Margin	78.2%	78.2%	78.3%	77.9%	77.6%	78.7%	78.9%	80.6%	78.5%
Total Operating Expenses	3.176B	774.600M	858.700M	784.500M	758.700M	716.300M	781.000M	740.900M	723.400M
Research & Development	1.088B	263.300M	267.700M	280.700M	276.200M	254.600M	271.100M	253.400M	272.600M
Selling, General & Administrative	2.142B	522.200M	602.900M	514.600M	502.000M	465.700M	491.900M	421.400M	450.800M
Operating Income (EBIT)	1.741B	514.700M	370.300M	425.100M	430.900M	394.800M	312.600M	350.600M	364.700M
Operating Margin	31.2%	31.2%	23.6%	27.4%	28.1%	27.9%	22.6%	25.9%	26.3%
Income Before Tax (EBT)	1.298B	459.000M	90.400M	348.400M	400.200M	433.900M	390.100M	402.800M	386.600M
Interest Income	145.400M	33.500M	35.900M	38.600M	37.400M	19.500M	44.200M	23.500M	16.500M
Interest Expense	—	—	—	—	—	—	—	—	—
Other Income/Expense	-443.000M	-55.700M	-279.900M	-76.700M	-30.700M	39.100M	77.500M	52.200M	21.900M
Net Income	1.093B	380.700M	91.200M	291.100M	329.800M	358.000M	385.600M	3.071B	363.700M
Income Tax Expense	224.900M	78.300M	26.200M	56.100M	64.300M	70.300M	45.100M	40.700M	20.200M
Net Profit Margin	23.1%	23.1%	5.8%	18.7%	21.5%	25.3%	27.8%	226.7%	26.2%
EBITDA	1.902B	555.600M	413.000M	464.300M	469.000M	431.400M	355.200M	385.100M	404.300M
EBITDA Margin	33.7%	33.7%	26.3%	29.9%	30.6%	30.5%	25.6%	28.4%	29.2%
Depreciation & Amortization	160.900M	40.900M	42.700M	39.200M	38.100M	36.600M	42.600M	34.500M	39.600M
EPS Basic	1.89	0.66	0.16	0.50	0.57	0.61	0.65	5.14	0.61
EPS Diluted	1.88	0.66	0.16	0.50	0.56	0.61	0.65	5.13	0.61
Shares Outstanding	579.200M	579.200M	580.400M	584.700M	587.000M	586.900M	589.800M	597.200M	602.100M
Diluted Shares Outstanding	580.700M	580.700M	581.800M	585.700M	587.900M	587.800M	590.500M	598.100M	604.300M

Annual Income Statement (USD)

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	6.068B	5.439B	5.010B	5.382B	5.232B	4.386B	4.348B	3.723B
Cost of Goods Sold	1.327B	1.117B	1.037B	1.167B	1.226B	1.099B	1.155B	922.100M
Gross Profit	4.741B	4.322B	3.973B	4.215B	4.007B	3.287B	3.193B	2.801B
Gross Profit Margin	78.1%	79.5%	79.3%	78.3%	76.6%	74.9%	73.4%	75.2%
Total Operating Expenses	3.104B	2.943B	2.545B	2.513B	2.396B	1.991B	1.995B	1.708B
Research & Development	1.079B	1.053B	962.900M	945.200M	903.100M	760.700M	752.700M	622.200M
Selling, General & Administrative	2.085B	1.789B	1.583B	1.568B	1.493B	1.231B	1.242B	1.086B
Operating Income (EBIT)	1.636B	1.379B	1.427B	1.702B	1.610B	1.296B	1.198B	1.092B
Operating Margin	27.0%	25.3%	28.5%	31.6%	30.8%	29.5%	27.6%	29.3%
Income Before Tax (EBT)	1.273B	1.548B	1.372B	1.767B	1.702B	916.700M	1.167B	761.400M
Interest Income	148.400M	120.300M	67.200M	35.500M	17.400M	23.400M	32.200M	32.000M
Interest Expense	—	19.800M	17.600M	26.200M	24.800M	22.200M	27.300M	33.400M
Other Income/Expense	-363.300M	169.400M	-54.900M	65.000M	91.600M	-379.300M	-31.400M	-330.900M
Net Income	1.073B	4.175B	1.402B	1.522B	1.503B	823.400M	1.047B	722.200M
Income Tax Expense	216.900M	152.100M	152.400M	245.500M	198.900M	93.300M	119.600M	39.200M
Net Profit Margin	17.7%	76.7%	28.0%	28.3%	28.7%	18.8%	24.1%	19.4%
EBITDA	1.793B	1.534B	1.572B	1.869B	1.774B	1.431B	1.313B	1.170B
EBITDA Margin	29.5%	28.2%	31.4%	34.7%	33.9%	32.6%	30.2%	31.4%
Depreciation & Amortization	156.600M	155.200M	144.900M	166.800M	163.300M	135.400M	114.600M	77.400M
EPS Basic	1.84	6.98	2.31	2.46	2.41	1.32	1.68	1.15
EPS Diluted	1.83	6.97	2.30	2.44	2.38	1.30	1.64	1.13
Shares Outstanding	584.800M	597.700M	606.700M	619.000M	623.300M	622.600M	624.900M	627.600M
Diluted Shares Outstanding	585.800M	599.300M	609.400M	624.200M	631.200M	631.900M	636.600M	640.800M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Irvine, CA

15,800 employees

www.edwards.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Bernard J. Zovighian

View full financials